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ABSTRACT
Background Isolated complex II deﬁciency is a rare
form of mitochondrial disease, accounting for
approximately 2% of all respiratory chain deﬁciency
diagnoses. The succinate dehydrogenase (SDH) genes
(SDHA, SDHB, SDHC and SDHD) are autosomally-
encoded and transcribe the conjugated heterotetramers
of complex II via the action of two known assembly
factors (SDHAF1 and SDHAF2). Only a handful of reports
describe inherited SDH gene defects as a cause of
paediatric mitochondrial disease, involving either SDHA
(Leigh syndrome, cardiomyopathy) or SDHAF1 (infantile
leukoencephalopathy). However, all four SDH genes,
together with SDHAF2, have known tumour suppressor
functions, with numerous germline and somatic
mutations reported in association with hereditary cancer
syndromes, including paraganglioma and
pheochromocytoma.
Methods and results Here, we report the clinical and
molecular investigations of two patients with
histochemical and biochemical evidence of a severe,
isolated complex II deﬁciency due to novel SDH gene
mutations; the ﬁrst patient presented with
cardiomyopathy and leukodystrophy due to compound
heterozygous p.Thr508Ile and p.Ser509Leu SDHA
mutations, while the second patient presented with
hypotonia and leukodystrophy with elevated brain
succinate demonstrated by MR spectroscopy due to a
novel, homozygous p.Asp48Val SDHB mutation. Western
blotting and BN-PAGE studies conﬁrmed decreased
steady-state levels of the relevant SDH subunits and
impairment of complex II assembly. Evidence from yeast
complementation studies provided additional support for
pathogenicity of the SDHB mutation.
Conclusions Our report represents the ﬁrst example of
SDHB mutation as a cause of inherited mitochondrial
respiratory chain disease and extends the SDHA mutation
spectrum in patients with isolated complex II deﬁciency.
INTRODUCTION
In eukaryotic cells, the mitochondrial oxidative
phosphorylation (OXPHOS) pathway is the primary
mechanism for ATP production. This OXPHOS
system comprises ﬁve transmembrane complexes
consisting of ∼90 protein subunits that are encoded
by the mitochondria’s own genetic material
(mtDNA) and the nuclear genome. Electrons,
supplied by the oxidation of fat and carbohydrates,
are transferred through the mitochondrial respira-
tory chain complexes to complex V, where oxygen
acts as the ultimate electron acceptor. Coincident
with electron transfer is the extrusion of protons
across the inner membrane from the matrix to the
intermembrane space, creating an electrochemical
gradient which is dissipated through complex V
(ATP synthase) driving the phosphorylation of ADP
to form ATP. Mitochondrial respiratory chain disease
represents a major inborn error of metabolism and is
caused by defective OXPHOS.1 Mitochondrial
disease is associated with both a varied age of onset
and a diverse phenotypic spectrum.2 The hallmark
clinical and genetic heterogeneity is often com-
pounded further by the lack of clear genotype–
phenotype correlations. Biochemical assessment of
respiratory chain complex activities can often
provide guidance for the genetic testing strategy, but
uncovering the underlying genetic defect can be
difﬁcult. For many patients, especially children,
the genetic aetiology of their condition remains
unknown.
Complex II differs from the other complexes of
the mitochondrial respiratory chain in that its four
structural subunits (SDHA, SDHB, SDHC and
SDHD) and two known assembly factor genes
(SDHAF1 and SDHAF2) are all nuclear-encoded.
The soluble ﬂavoprotein (Fp/SDHA) and iron–
sulphur (Fe-S/SDHB) proteins, encoded by SDHA
and SDHB, respectively, have catalytic activity and
together form succinate dehydrogenase (SDH),
while the SDHC and SDHD subunits act to anchor
the complex to the inner mitochondrial membrane
and its interaction with the quinone pool.3
Complex II is also unique in that it is part of both
the respiratory chain and the Krebs cycle.
Mitochondrial disease presentations associated
with an isolated deﬁciency of complex II are rare,
accounting for an estimated 2% of respiratory chain
deﬁciencies.4 5 Reported cases have presented in
childhood with Leigh syndrome,4 6–8 a fatal respira-
tory disease with severe hypoglycaemia,9 neonatal
cardiomyopathy10 and an infantile leukoencephalo-
pathy.11 The only reported exception to these child-
hood presentations is the report of two sisters with
an adult-onset phenotype characterised by progres-
sive optic atrophy, ataxia and myopathy.12
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In addition to primary mitochondrial disease presentations,
germline mutations in SDHA,13 SDHB,14 SDHC,15 SDHD16 17
and SDHAF218 are recognised causes of familial pheochromocy-
tomas and paragangliomas, thus establishing a link between
SDH deﬁciency and susceptibility to tumourigenesis.19 The
factors determining whether SDH defects lead to neurological
disease or impaired tumour suppression are poorly understood,
yet both are related to loss of enzyme activity and perturbation
of the complex formation. On account of its similarity with
the human enzyme, the Saccharomyces cerevisiae has proven a
useful model system to study the effects of SDH gene muta-
tions, in particular germline missense mutations associated
with paraganglioma development.20
Here, we report two paediatric patients presenting with leu-
koencephalopathy with isolated complex II deﬁciency in whom
molecular investigations revealed novel compound heterozy-
gous p.Thr508Ile and p.Ser509Leu SDHA mutations in one
patient, and a novel, homozygous p.Asp48Val SDHB mutation
in the second. This represents the ﬁrst example of
SDHB-related pathology in association with a primary mito-
chondrial disease presentation, with pathogenicity conﬁrmed
by functional modelling studies in yeast.
SUBJECT AND METHODS
Patient 1
Patient 1 is a male child born at term to non-consanguineous,
mixed ethnicity parents following an uncomplicated pregnancy.
He was well during the neonatal period, but at 3 months of
age he presented with increasing dyspnoea, sweating and difﬁ-
culty feeding. Cardiomegaly was evident on chest radiograph
(ﬁgure 1A) while echocardiogram demonstrated ischaemia and
a dilated and markedly hypertrophied left ventricle, with a
degree of non-compaction of the left ventricular myocardium
and a fractional shortening of only 10%. Cardiac catheter inves-
tigation demonstrated no abnormality of the coronary arteries,
and he was diagnosed with dilated cardiomyopathy. Cardiac
function improved and stabilised with short-term inotropic
support, ongoing diuretic therapy and ACE inhibitors.
Initial development was satisfactory so that by 8 months of
age he could sit unsupported, roll over, pull to stand and was
babbling. However, motor delay was noted by 18 months of
age. At review at 2.5 years of age, he was able to stand, but
with knees and hips in ﬂexion due to contractures. He had a
few single words of speech. Examination revealed generalised
hypertonia in all limbs with brisk deep tendon reﬂexes and
bilateral upgoing plantar response.
Cranial and spinal MRI at 2.5 years age (ﬁgure 1B) demon-
strated extensive cystic change and abnormal high T2 and
FLAIR signal in the central cerebral white matter symmetrically
and bilaterally, with scattered peripheral foci of abnormal
signal in the frontal lobes. There was also abnormal signal in
the anterior and posterior corpus callosum, ventral pons,
medulla and throughout the majority of the grey matter of the
spinal cord (ﬁgure 1C). Metabolic investigations included
normal random plasma lactate (1.5 mmol/l). Acylcarnitine
proﬁle demonstrated increased acetyl and hydroxybutyryl carni-
tines consistent with ketosis/lactic acidosis, with a normal free
carnitine concentration. Urinary amino acids were normal,
while organic acids demonstrated raised lactate, ketones and
3-hydroxyisovalerate and elevated tricarboxylic acid cycle meta-
bolites (succinate, fumarate and 2-ketoglutarate). A diagnostic
open skeletal muscle biopsy was obtained at 3 years of age.
Patient 2
Patient 2 is a female child born at term to consanguineous Asian
parents. There were no antenatal or perinatal complications, no
previous history of miscarriages, and two older siblings are alive
and well. Growth and developmental milestones were normal
until 1 year of age by which time she could cruise around furni-
ture and was babbling. Subsequently, over a 6-week period, she
lost the ability to walk, became unsteady and had repeated falls.
There was no associated head injury or febrile illness. She
became very hypotonic with poor head control and difﬁculty
feeding. After the 6-week period of deterioration she made slow
developmental progress, and there were no further episodes of
developmental regression. By the age of 4 years, she could stand
Figure 1 (B) Axial T2-weighted MR image of Patient 1’s brain demonstrates high signal intensity in frontal (arrow) and peritrigonal (arrow head)
white matter sparing subcortical U-ﬁbres, normal basal ganglia whilst the sagittal T2-weighted spinal image (C) demonstrates extensive high signal
intensity in spinal cord grey matter (arrow heads).
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brieﬂy with support although remains wheelchair-dependent,
having developed ﬂexion contractures in both her arms and legs.
MRI acquired at the initial presentation (ﬁgure 1D) revealed
leukodystrophy with extensive signal changes in the deep cere-
bral white matter, sparing U-ﬁbres, with abnormalities also
present in cerebellum and brainstem. A repeat brain MRI study
at 4.5 years (ﬁgure 1E) revealed a similar pattern of abnormal-
ities but with cyst formation in the abnormal white matter,
and persistent signal abnormalities in the corpus callosum. The
short echo time MR spectroscopy of the dystrophic white
matter (ﬁgure 1G) demonstrated the presence of a singlet
lactate peak at 2.4 ppm, seen also in long echo time (not
shown) but not detected in a control group or in the normal
appearing basal ganglia of patient 2 (ﬁgure 1H),21 conﬁrming
the accumulation of succinate in the dystrophic white matter
in vivo. The metabolite proﬁle of the white matter also demon-
strated signiﬁcantly decreased glutamine and glutamate, rela-
tive preservation of the neuronal marker N-acetylaspartate and
increased myo-inositol compared with a previously reported
age-matched cohort.22 The metabolite proﬁle of the unaffected
basal ganglia appeared relatively normal with no succinate
detected (ﬁgure 1F).
Metabolic investigations demonstrated normal plasma, very
long chain fatty acids, carnitine proﬁle, amino acids, ammonia
and lactate. Urinary organic and amino acids, glycosaminogly-
cans and oligosaccharides were also normal, as were cerebro-
spinal ﬂuid glucose and lactate. A diagnostic open skeletal
muscle biopsy was obtained at age 5 years.
Muscle histology and biochemistry
Informed consents with appropriate ethics review committee
approvals were obtained. Histological and histochemical ana-
lyses were performed on 10 mm transversely-orientated serial
cryosections of skeletal muscle biopsy samples using standard
procedures. The activities of individual respiratory chain
complex activities and citrate synthase, a mitochondrial matrix
marker, were determined in muscle homogenates as previously
described.23
Molecular genetics
Total genomic DNA was obtained using standard methods and
the coding region plus intron–exon boundaries of the SDHA,
SDHB and SDHAF1 genes were ampliﬁed using locus speciﬁc
primers (sequences available upon request). Amplicons were
sequenced using the BigDye v3.1 kit and capillary electrophor-
esed on the ABI3130×l ﬂuorescent sequencing platform
(Life Technologies, Warrington, UK). Chromatograms were
compared with appropriate GenBank reference sequences
(SDHAF1: NM_001042631.2; SDHA: NM_004168.2; and
SDHB: NM_003000.2). All sequence variants were cross-refer-
enced against dbSNP (build 135) and all variants of unknown
pathological signiﬁcance were investigated using in silico
methodologies.24–27
In silico prediction tools
Amino acid residue conservation and predicted impact of the
novel SDHA and SDHB variants were investigated using
Ensembl release 66,24 Polyphen2,25 SIFT26 and AlignGVGD.27
Putative effects of the novel SDHB variant on SDHB tertiary
structure were proposed using Phyre2,28 while residue interac-
tions between the SDH subunits were characterised using
Piccolo.29 Sequence alignment for mutation analysis was per-
formed with Clustal30 and BLAST.31
BN-PAGE and SDS-PAGE
Blue native polyacrylamide gel electrophoresis (BN-PAGE) was
used to investigate the native structures of respiratory chain
enzymes. For BN-PAGE, the NativePAGE Novex Bis-Tris Gel
and blot transfer system was used and samples were run using
precast 4%–16% Bis-Tris gels (Invitrogen, Carlsbad, California,
USA). For Patient 2 and two aged-matched controls, enriched
mitochondria were prepared from muscle using differential cen-
trifugation after homogenisation in Medium A (120 mM KCl,
20 mM HEPES, 5 mM MgCl2, 1 mM EGTA, pH 7.2). For
Patient 1 and two separate paediatric controls, mitochondria
were isolated from cultured ﬁbroblasts as described32 using
anti-TOM22 coated MicroBead system (Miltenyi Biotec,
Bergisch Gladbach, Germany). Protein content was determined
using Bradford reagent (Bio-Rad, Hercules, California, USA)
and between 2 and 10 mg of mitochondria were loaded, depend-
ing on the postrun analysis. For Patient 1 and controls,
complex I ingel activity analysis was performed.33 Following
western blot transfer of BN-PAGE gels, complexes I and II were
probed with mouse antihuman immunoglobulin directed at
NDUFA9 and the ﬂavoprotein and iron–sulphur subunits of
SDH, respectively. All primary antibodies, except TOM20
(Santa Cruz, Biotechnology, Santa Cruz, California, USA),
were purchased from Mitosciences/Abcam (Cambridge, UK).
Proteins were separated by SDS-PAGE, transferred and mem-
branes probed with antibodies against SDHA, SDHB and
NDUFB8 as well as porin or TOM20 (as mitochondrial loading
markers). For detection, blots were treated with appropriate
HRP-conjugated immunoglobulins (Dako, Glostrup, Denmark),
followed by ChemiLucent detection reagents (GE Healthcare,
Buckinghamshire, UK).
Yeast strains and culture conditions
Yeast strains, BY4741 (MATa; his3D1 leu2D0 lys2D0 ura3D0)
and its isogenic sdh2:kanMX4 mutant, were transformed using
the lithium acetate method.34 Restriction-enzyme digestions,
Escherichia coli transformation and plasmid extractions were per-
formed using standard methods.35
Cells were cultured in yeast nitrogen base (YNB) medium
(0.67% YNB without amino acids (ForMedium, Hunstanton,
UK)) supplemented with 1 g/l of drop-out powder36 containing
all amino acids except those required for plasmid maintenance.
Various carbon sources were added at 2% (w/v) (Carlo Erba
Reagents, Milan, Italy). Media were solidiﬁed with 20 g/l agar
(ForMedium). For respiration and mitochondria extraction, cells
were grown to late-log phase in the YNB medium supplemen-
ted with 0.6% glucose.
Construction of yeast mutant alleles
The sdh2 p.Asn42Asp and p.Asn42Val mutant alleles were
obtained by site-directed mutagenesis using the overlap exten-
sion technique.37 In the ﬁrst set of PCR reactions, the SDH2
region was obtained using the forward primer
HSDH2F-CGCGAAGCTTGCTGAGGTGCAAATGGCCACCC
and the following reverse mutagenic primers RS242ND-
GGTTTAGCACTTGGCTCGTCTGGGTCCCATCTGTAAACT-
TTAAAAG and RS242NV-GGTTTAGCACTTGGCTCGTCTGG
CACCCATCTGTAAACTTTAAAAG where base changes are
indicated in bold. The second SDH2 region was obtained using
the forward mutagenic primers FS242ND and FS242NV, com-
plementary to RS242ND and RS242NV, and the reverse primer
SSDH2R-CCCCGTCGCCACCTTGTCGCCTATGATGG. The
ﬁnal mutagenised products were obtained using the overlapping
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PCR fragments as template with HSDH2F and SSDH2R as
external primers. The products were then digested with HindIII
and SalI and cloned in HindIII-SalI digested pFL38 centromeric
plasmid.38
Isolation of mitochondria, enzyme assays and respiration
Oxygen uptake was measured at 30°C using a Clark-type
oxygen electrode in a 1 ml stirred chamber containing 1 ml of
air-saturated respiration buffer (0.1 M phthalate–KOH, pH 5.0)
and 10 mM glucose (Oxygraph System, Hansatech Instruments,
England). The reaction was initiated with the addition of 20 mg
of wet weight of cells, as described.20 Preparation of mitochon-
dria and SDH activity (expressed as nmol/min/mg protein) were
also performed as described.20
RESULTS
Histological, histochemical and respiratory chain analyses
The histological examination of diagnostic skeletal muscle biop-
sies was normal for both patients, with the exception of a few
atrophic ﬁbres in Patient 1, and a subtle increase in intraﬁbre
lipid content for Patient 2 (ﬁgure 2). Histochemical analysis of
both patients’ biopsies demonstrated normal cytochrome c
oxidase reactions, with no evidence of mitochondrial prolifer-
ation, but severe deﬁciencies in SDH activity (ﬁgure 2C,G)
compared with age-matched control muscle. This was con-
ﬁrmed by the spectrophotometric assay of respiratory chain
activities, which demonstrated a severe and isolated deﬁciency
involving complex II in muscle homogenates from both
patients (table 1).
Molecular genetic analysis
Sequencing of the SDHAF1 gene in both patients revealed no
known or potentially pathogenic mutations. Analysis of the
coding region of the SDHA gene in Patient 1 revealed two novel
heterozygous variants affecting adjacent amino acids within
exon 11; a c.1523C>T transition predicting a p.Thr508Ile sub-
stitution and a c.1526C>T transition predicting a p.Ser509Leu
substitution within the catalytic ﬂavoprotein subunit of
complex II (ﬁgure 3A). The lack of an SDHA or SDHAF1 defect
in Patient 2 prompted analysis of the SDHB gene, identifying a
novel homozygous c.143A>T SDHB transversion in exon 2
that predicts a p.Asp48Val substitution within the catalytic
iron–sulphur subunit of SDH (ﬁgure 3B). Recessive inheritance
of all variant alleles was conﬁrmed by screening parental DNA
samples (see ﬁgure 3A,B). In silico predictions regarding the
putative functional effects of the p.Thr508Ile and p.Ser509Leu
SDHA and p.Asp48Val SDHB variants supported a deleterious
aetiology. Phyre2 and Piccolo modelling revealed no obvious
conformational differences between predicted tertiary struc-
tures of the wild-type and mutant SDHA and SDHB proteins.
Western blotting
To assess the impact of the novel SDHA and SDHB variants on
the steady-state levels of complex II and the respective subu-
nits’ stability, BN-PAGE and SDS-PAGE analyses were per-
formed on available material from the two patients. BN-PAGE
analysis using isolated mitochondria from cultured ﬁbroblasts
of Patient 1 revealed a signiﬁcantly decreased amount of fully
assembled complex II compared with aged-matched controls
(ﬁgure 4A). In contrast, comparatively higher complex I in-gel
activities were noted in this patient. SDS-PAGE analysis con-
ﬁrmed an almost complete absence of SDHA in the patient,
relative to the mitochondrial loading marker, porin. BN-PAGE
analysis using enriched skeletal muscle mitochondria from
Patient 2 showed a relative lower amount of fully assembled
complex II compared with complex I (ﬁgure 4B), while
SDS-PAGE analysis demonstrated an almost complete absence
of the SDHB subunit compared to both control samples and
mitochondrial loading controls. In addition, expression of the
SDHA subunit of complex II also appeared to be decreased,
suggesting instability of the assembled complex.
Complementation studies in yeast of human
SDHB mutant alleles
To validate the pathogenic role of the p.Asp48Val SDHB muta-
tion in Patient 2, we performed complementation studies using
the Saccharomyces cerevisae strain BY4741, deleted in the SDH2
gene (the yeast orthologue of mammalian SDHB), hereafter
Figure 2 (A–C) H&E staining, cytochrome c oxidase (COX) histochemistry and succinate dehydrogenase (SDH) histochemistry respectively, for
Patient 1, indicating a marked decrease in the activity of SDH (C) compared with a control SDH reaction (D). (E–H) Images from the muscle biopsy
of Patient 2 including H&E staining (E), COX histochemistry reactivity (F), SDH histochemistry reactivity (G) and the Oil Red O stain (H), the last
highlighting a very subtle increase in intraﬁbre lipid.
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referred to as Δsdh2 strain. The mutated SDHB residue
p.Asp48Val is not conserved between human and yeast;
Aspartate-48 in human SDHB is conservatively substituted by
Asparagine-42 in the yeast Sdh2 protein (ﬁgure 5A). We there-
fore constructed the ‘humanised wild-type’ allele by replacing
the codon speciﬁc to the amino acid residue of the wild-type
SDH2 yeast sequence, with the codon corresponding to the
amino acid residue of the wild-type SDHB human sequence.
The humanised wild-type SDH2 variant allele (p.Asn42Asp)
was then introduced into Δsdh2 yeast mutant and the
transformants were tested for oxidative growth on YNB
medium supplemented with 2% ethanol or 2% acetate (ﬁgure
5B). The ‘humanised allele’ was able to complement the oxida-
tive growth defect of Δsdh2 strain.
We then prepared the second construct by introducing the
p.Asn42Val substitution, corresponding to the purported patho-
genic mutant residue in the SDHB protein of Patient 2, and
measured its effect on oxidative growth, SDH activity and res-
piration. Growth on 2% ethanol and 2% acetate was barely
impaired in transformants carrying the p.Asn42Val substitution
(ﬁgure 5B). When respiration was measured, both strains
sdh2p.Asn42Asp and sdh2p.Asn42Val displayed an oxygen con-
sumption rate equivalent to that of the wild-type strain, sug-
gesting that decreased SDH activity does not impair electron
ﬂux through the respiratory chain (ﬁgure 5C). We then studied
the effect of both the sdh2p.Asn42Val mutation and sdh2p.
Asn42Asp humanised wild-type variant on SDH enzyme activ-
ity. The results obtained indicated that the SDH activity was
reduced by approximately 50% in the strain harbouring the
p.Asn42Val mutant allele whereas the SDH activity of the
humanised wild-type allele was indistinguishable from that of
the parental strain (ﬁgure 5D).
Table 1 Assessment of patient respiratory chain complex activities in
skeletal muscle homogenate
Complex I/CS Complex II/CS Complex III/CS Complex IV/CS
Patient 1 0.065 0.022 1.158 0.701
Patient 2 0.182 0.049 0.705 0.475
Controls
(n=25)
0.104±0.036 0.145±0.047 0.554±0.345 1.124±0.511
Enzyme activities are expressed as nmol NADH oxidised min/unit citrate synthase (CS)−1
for complex I, nmol DCPIP reduced min/unit citrate synthase−1 for complex II (succinate to
ubiquinone-1 reductase) and the apparent first-order rate constant s/ unit citrate
synthase−1 for complexes III and IV (×103). Control values are shown as mean±SD.
DCPIP, 2,6-dichlorophenol-indophenol.
Figure 3 Identiﬁcation of pathogenic SDHA and SDHB mutations. (A) Compound heterozygous c.1523C>T (p.Thr508Ile) and c.1526C>T
(p.Ser509Leu) SDHA mutations were identiﬁed in Patient 1, with parental DNA screening supporting recessive inheritance. Both mutations affect
highly conserved p.Thr508 and p.Ser509 residues in the SDHA-encoded subunit A of succinate dehydrogenase (SDH). (B) A novel homozygous
c.143A>T (p.Asp48Val) SDHB mutation was identiﬁed in Patient 2, with recessive inheritance supported by parental DNA screening. Multiple
sequence alignment of this region of the SDHB subunit conﬁrms that p.Asp48Val mutation affects an evolutionary conserved residue.
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DISCUSSION
Mitochondrial complex II is a critical enzyme for cellular respir-
ation and despite its key roles in both the Krebs cycle and the
electron transport chain, it represents a rare cause of disease in
the general population. Given that so few Krebs cycle enzyme
deﬁciencies are reported, bi-allelic mutations affecting these
enzymes appear to be typically incompatible with life; all
reported cases are recessive and involve isolated deﬁciencies of
fumarate hydratase, SDH and, most recently, aconitase,39 and
are associated with a severe neurological phenotype and very
poor prognosis, being almost always fatal in the neonatal
period. Conversely, OXPHOS disease presentations are com-
paratively common, can present at any stage throughout life
and are associated with vast clinical and genetic heterogeneity.
Pathogenic mutations have been identiﬁed in numerous
OXPHOS genes, but the correlation with clinical phenotype is
rarely pathognomonic. Isolated deﬁciencies involving SDH are
the rarest of all OXPHOS deﬁciencies, accounting for approxi-
mately 2% of all mitochondrial disease cases.
Here, we describe two children who presented during
infancy with motor manifestations of leukodystrophy and one
who also had signiﬁcant cardiomyopathy, in whom biochem-
ical and histochemical analyses of respiratory chain activities in
skeletal muscle uncovered a severe, isolated deﬁciency of
complex II. Mutations in SDHAF1 and SDHA genes are known
to cause mitochondrial complex II deﬁciency;7 10 11 thus,
sequencing of these genes was prioritised. This analysis revealed
novel compound heterozygous variants of unknown patho-
logical signiﬁcance within the SDHA gene (c.1523C>T;
p.Thr508Ile and c.1526C>T; p.Ser509Leu) for Patient 1, while
analysis of the SDHAF1 and SDHA genes for Patient 2 revealed
only wild-type sequence. A candidate gene sequencing approach
led to the discovery of a novel homozygous (c.143A>T;
p.Asp48Val) SDHB variant in Patient 2. Recessive inheritance of
the SDHA and SDHB variants was conﬁrmed by parental DNA
screening. Functional investigations supported the deleterious
effect of the putative SDHA and SDHB mutations, with
SDS-PAGE, BN-PAGE and western blotting conﬁrming
decreased levels of SDHA and SDHB protein expression for
Patients 1 and 2, respectively; both patients had a marked
reduction in stable, fully-assembled complex II.
While there are numerous reports describing SDHB muta-
tions in the context of hereditary and sporadic cancer path-
ology, this report represents the ﬁrst case of SDHB mutation in
association with a neurological phenotype. Additional func-
tional evidence supporting the pathogenicity of the novel
homozygous SDHB mutation was provided through modelling
the p.Asp48Val mutation in Saccharomyces cerevisae Despite a
very high degree of conservation across the SDHB/SDH2 genes,
a lack of homology at the human p.Asp48 SDHB locus and cor-
responding Saccharomyces cerevisae p.Asn42 residue was noted
and addressed in our experimental design. Site-directed muta-
genesis was employed to generate a p.Asn42Val mutant, in
which a marked decrease in SDH activity was observed. A
humanised wild-type yeast model was subsequently generated
to investigate whether the lack of homology at the p.Asn42/
p.Asp48 locus impacted upon SDH activity; SDH activity in
the humanised p.Asp42 and wild-type Sdh2 model were com-
parable, thus corroborating the pathogenicity of the human
p.Asp48Val mutation.
Based on Piccolo modelling, the wild-type human p.Asp48
residue is not involved in direct binding to other SDH residues
but is located within the highly conserved 2Fe-2S binding
domain of the SDHB protein. While p.Asp48 has no obvious
primary interaction with other residues of the complex, we
hypothesise that it is critical for efﬁcient binding and onward
procession of electrons within the mitochondrial respiratory
chain.
Figure 4 Investigation of complex
activities and protein expression in
Patients 1 and 2 and controls.
(A) BN-PAGE analysis of mitochondria
isolated from cultured patient and
control ﬁbroblasts revealed a reduction
of assembled complex II. SDS-PAGE
analysis, probed with antibodies
against porin (loading control) and the
ﬂavoprotein subunit of succinate
dehydrogenase (SDH), revealed an
almost complete obliteration of SDHA
expression for Patient 1, corroborating
the pathogenicity of the c.1523C>T
(p.Thr508Ile) and c.1526C>T
(p.Ser509Leu) SDHA variants.
(B) BN-PAGE analysis of enriched
mitochondria from patient and control
muscle revealed a reduction of
complex II assembly, with normal
complex I assembly. SDS-PAGE
analysis shows a gross decrease in
iron–sulphur (SDHB) and a slightly
reduction in SDHA subunit expression,
with normal levels of TOM20 and
porin.
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We provide functional evidence linking the primary SDHB
defect with speciﬁc brain pathology. The abnormal MRI signal
intensities in brain are restricted to the white matter and indi-
cative of myelin or glial pathology (ie, leukodystrophy); such
anomalies have been described in mitochondrial disease, while
the spinal cord changes as seen in Patient 1 have been
described in mitochondrial pathologies including leukoence-
phalopathy with brain stem and spinal cord involvement and
lactate elevation (LBSL).40 The accumulation of succinate
detectable in the occipito-parietal (clinically affected) region
by MRS provides further evidence of a metabolic aetiology;
elevated succinate on MRS imaging investigations could be a
key diagnostic indicator of SDH deﬁciency with the elevated
metabolite levels reﬂecting ‘enzymatic cascade stalling’ and
MRS should be considered in patients with suspected mito-
chondrial disease. Succinate inhibits prolyl hydroxylase activ-
ity, which stabilises hypoxia-inducible factor (HIF1α) under
‘normal’ anaerobic conditions (eg, exercise or high altitude)
and triggers hypoxia-inducible pathways. In the case of SDH
deﬁciency, metabolic stalling generates an accumulation of suc-
cinate that mimics this process.41 This report provides mech-
anistic evidence illustrating a link between speciﬁc white
matter changes and SDH deﬁciency. The factors determining
localisation of these effects to speciﬁc brain regions remain
unclear.
In addition to their recognised role in cellular respiration,
SDHA, SDHB, SDHC, SDHD and SDHAF2 have all been
shown to possess tumour suppressor functionality, with loss of
heterozygosity of SDH gene germline mutations leading to cel-
lular proliferation in paraganglioma and pheochromocytoma,13–
15 42 GIST,43 small cell renal carcinoma44 and neuroblastoma.45
The reported penetrance of SDHB mutations is the highest of
all SDH genes in familial cases of head and neck paraganglioma
and pheochromocytoma, being associated with early-onset
tumourigenesis.44 The link between SDH defects and tumouri-
genesis can be made on more than one level. First, characterised
by the Warburg effect, the ability of tumours to switch from
aerobic to anaerobic/glycolytic respiration is key for immortal-
isation.46 Second, succinate-directed activation of the HIF
pathway inhibits apoptosis and stimulates angiogenesis.47 48
Moreover, there is evidence supporting an increase of reactive
oxygen species (ROS) in systems with SDH deﬁciencies;
increased ROS is a recognised cause of DNA damage, further
compounding the already mounting oncogenic pressures on the
Figure 5 Complementation studies in yeast conﬁrming pathogenicity of the p.Asn42Val SDHB mutation. (A) ClustalW alignment of the yeast and
human SDHB homologues conﬁrm that although the amino acid sequences are highly conserved, the p.Asp48 residue in human SDHB is not
conserved in yeast, with the corresponding SDH2 residue being p.Asn42. (B) Oxidative growth phenotype. The strain BY4741 sdh2Δ was
transformed with either pFL38 empty vector, pFL38 carrying the wild-type SDH2, the humanised wild-type (sdh2N42D) allele or the pathological
(sdh2N42V) allele. Equal amounts of serial dilutions of cells from exponentially grown cultures (105, 104, 103, 102 and 101 cells) were spotted onto
yeast nitrogen base (YNB) plates supplemented with 2% glucose or with 2% ethanol. The growth was scored after 5 days of incubation at 28°C.
(C) Respiration was measured in cells grown in YNB supplemented with 0.6% glucose. aAllele carried by the vector introduced into the null Δsdh2
strain; bexpressed as nmol O2/min/mg dry weight. Each value is the mean of three independent experiments. (D) Assessment of succinate
dehydrogenase (SDH) activity. Enzyme activity was measured in mitochondria isolated from cells grown to late exponential phase at 28°C in YNB
supplemented with 0.6% glucose. The values of the sdh2 mutants are expressed as percentage of the activities obtained in the sdh2Δ/SDH2. Values
are means of three independent experiments in duplicate.
J Med Genet 2012;49:569–577. doi:10.1136/jmedgenet-2012-101146 575
Genotype-phenotype correlations
cell, increasing the likelihood of transformation to immortalised
cell status.41
Proving the pathogenicity of candidate gene mutations is
always important, perhaps more so when the genes involved are
also tumour suppressors. Having conﬁrmed the SDH mutation
as pathogenic, there are further ethical considerations with
regard to disclosure of carrier status and prenatal testing. A child
born to carrier parents has a 25% risk of a severe neurological
phenotype, a 50% risk of ‘elevated cancer susceptibility’ and in
the situation where only one parent harbours a SDHB mutation,
a 50% risk of elevated cancer susceptibility. The issue of whether
clinicians should be able to reveal carrier status as well as ‘clinic-
ally affected’ status during prenatal screening is one that should
be considered indepth, particularly if there is evidence of onco-
genesis in relation to the SDH gene mutation in question.
While the recessive genetic defects in SDHA and SDHB iden-
tiﬁed in the two probands described here have caused severe
neurological presentations and complex II deﬁciency, the fact
that the parents of Patients 1 and 2 are heterozygous carriers of
germline SDH mutations may place them at an elevated risk of
tumourigenesis although neither the SDHA (p.Ala508Thr and
p.Ser509Thr) nor SDHB (p.Asp48Val) mutations are reported
in the Leiden Open Variation Database (http://chromium.liacs.
nl/LOVD2/SDH/home.php), suggesting that these particular
mutations have not yet been linked to tumourigenesis.
Although there is no indication of cancer susceptibility in
either family, both families have been referred for surveillance.
As with the majority of mitochondrial disease presentations,
there are no effective cures for SDH deﬁciency although riboﬂavin
has been shown to alleviate some of the symptoms and delay
disease progression.49 Following the diagnosis of SDH deﬁciency,
oral coenzyme Q10 treatment was commenced in Patient 2 and a
subjective improvement in strength was reported.
We recommend screening of the SDHA, SDHB and SDHAF1
genes for patients with a biochemically and histochemically
characterised isolated complex II deﬁciency. Identifying the
underlying genetic basis of isolated complex II deﬁciency is
vital to ensure that appropriate counselling is available for the
family. It facilitates access to cascade screening, and given the
increased cancer susceptibility, particularly in relation to SDHB
defects, routine surveillance would enable early detection of
tumours and appropriate intervention.
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